PRODUCT OVERVIEW
Wellness Footwear
.png)
Heelios Activation Technology is the world’s first continuous-delivery red + near-infrared photobiomodulation platform embedded directly into footwear insoles and midsoles. A patented silicone matrix emits proven wellness wavelengths (dominant peaks 630–670 nm & 688–700 nm) for the entire life of the shoe — no batteries, no charging, no wear-out. This turns any shoe into an active wellness device, supporting cellular vitality and micro-circulation with every step. Backed by clinical trials and real-world use, it's the scalable edge for brands and manufacturers.
How It Works
Heelios Activation starts with our patented silicone compounded with red + near-infrared emitters
.png)
standard manufacturing
It's integrated during standard manufacturing via PU pour crumb mix, sheet lamination, or liquid injection.
emits low-intensity
The material emits low-intensity 250–1100 nm light (peaks 630–700 nm) directly into foot tissue, enhancing local micro-circulation and cellular energy (ATP) continuously and passively.
.png)
circulation enhancement
Documented outcomes include up to 3× micro-circulation enhancement and significant user-reported comfort gains — all without adverse events.
.png)
The Problem
Consumers and professionals spend 8–16 hours a day on their feet, yet today’s footwear only manages impact and alignment. It does nothing to actively support cellular energy, micro-circulation, or all-day recovery — leaving billions of steps biologically “silent” in a market desperate for real wellness differentiation. In a $425B global footwear industry facing M&A frenzy, brands struggle to stand out with incremental tweaks, while manufacturers seek low-risk innovations to boost margins.
.png)
The Solution
Heelios turns every pair of shoes into an active wellness device. By embedding the exact same photobiomodulation silicone already used in 45,000+ commercial wellness units and 194-patient double-blind trials, we deliver clinically rooted cellular benefits with every step — at <$3 incremental cost and zero CapEx. This proprietary technology integrates seamlessly, unlocking premium pricing and loyalty in performance, occupational, and active-aging segments.
Key Features
Following are the key features:
.png)
Clinically documented material (3× micro-circulation, major comfort gains, zero adverse events).
Incremental cost $2.00 – $3.00 per pair.
Immediate HSA/FSA eligibility pathway in the U.S.
.png)
Heelios-owned footwear-specific IP (U.S. PPA filed, utility in progress).
Suggested royalty $10 – $18 → licensees retain 40–55 % gross margin.
Early traction secured: Validated by active discussions with leading global performance and lifestyle footwear brands.
Zero new equipment or tooling required.
Fully compatible with white-label, co-branding, or “Heelios Activated” badge.
60-day risk-free pilot available (we supply material at no charge).
%20(2).png)